264 related articles for article (PubMed ID: 24832560)
21. Fluoroquinolone prophylaxis in haematological cancer patients with neutropenia: ECIL critical appraisal of previous guidelines.
Mikulska M; Averbuch D; Tissot F; Cordonnier C; Akova M; Calandra T; Ceppi M; Bruzzi P; Viscoli C;
J Infect; 2018 Jan; 76(1):20-37. PubMed ID: 29079323
[TBL] [Abstract][Full Text] [Related]
22. Prophylaxis and treatment of bacterial infections: do we need new strategies?
Micozzi A; Bucaneve G
Rev Clin Exp Hematol; 2005 Dec; 9(2):E4. PubMed ID: 16864118
[TBL] [Abstract][Full Text] [Related]
23. Use of fluoroquinolones as prophylactic agents in patients with neutropenia.
Patrick CC
Pediatr Infect Dis J; 1997 Jan; 16(1):135-9; discussion 160-2. PubMed ID: 9002124
[TBL] [Abstract][Full Text] [Related]
24. Counterpoint: routine anti-bacterial prophylaxis is not indicated in neutropenic patients with hematological malignancies.
Kleinberg M
J Natl Compr Canc Netw; 2004 Sep; 2(5):445-51. PubMed ID: 19780253
[TBL] [Abstract][Full Text] [Related]
25. Fluoroquinolone prophylaxis in patients with neutropenia.
Zinner SH
Clin Infect Dis; 2005 Apr; 40(8):1094-5. PubMed ID: 15791506
[No Abstract] [Full Text] [Related]
26. Treatment with fluorated quinolones of febrile neutropenia in patients with hematologic malignancies.
Nenova IS; Goranov SE; Mateva NG; Ananoshtev NH
Folia Med (Plovdiv); 2003; 45(1):13-9. PubMed ID: 12943062
[TBL] [Abstract][Full Text] [Related]
27. The changing face of febrile neutropenia-from monotherapy to moulds to mucositis. Why empirical therapy?
Klastersky J
J Antimicrob Chemother; 2009 May; 63 Suppl 1():i14-5. PubMed ID: 19372173
[TBL] [Abstract][Full Text] [Related]
28. Impact of Fluoroquinolone Prophylaxis on Neutropenic Fever, Infections, and Antimicrobial Resistance in Newly Diagnosed AML Patients.
Caro J; Madero-Marroquin R; Zubizarreta N; Moshier E; Tremblay D; Coltoff A; Lancman G; Fuller R; Rana M; Mascarenhas J; Jacobs SE
Clin Lymphoma Myeloma Leuk; 2022 Dec; 22(12):903-911. PubMed ID: 36109322
[TBL] [Abstract][Full Text] [Related]
29. Antibiotic prophylaxis in neutropenic children with acute leukemia: Do the presently available data really support this practice?
Calitri C; Ruberto E; Castagnola E
Eur J Haematol; 2018 Dec; 101(6):721-727. PubMed ID: 30107054
[TBL] [Abstract][Full Text] [Related]
30. Retrospective analysis of fluoroquinolone prophylaxis in patients undergoing allogeneic hematopoietic stem cell transplantation.
Simondsen KA; Reed MP; Mably MS; Zhang Y; Longo WL
J Oncol Pharm Pract; 2013 Dec; 19(4):291-7. PubMed ID: 23184539
[TBL] [Abstract][Full Text] [Related]
31. Perils of quinolone exposure in cancer patients: breakthrough bacteremia with multidrug-resistant organisms.
Rangaraj G; Granwehr BP; Jiang Y; Hachem R; Raad I
Cancer; 2010 Feb; 116(4):967-73. PubMed ID: 20052728
[TBL] [Abstract][Full Text] [Related]
32. Cefpodoxime proxetil: a review of its use in the management of bacterial infections in paediatric patients.
Fulton B; Perry CM
Paediatr Drugs; 2001; 3(2):137-58. PubMed ID: 11269640
[TBL] [Abstract][Full Text] [Related]
33. Gram-negative organisms predominate in Hickman line-related infections in non-neutropenic patients with hematological malignancies.
Chee L; Brown M; Sasadeusz J; MacGregor L; Grigg AP
J Infect; 2008 Apr; 56(4):227-33. PubMed ID: 18342947
[TBL] [Abstract][Full Text] [Related]
34. Fluoroquinolone prophylaxis for bacterial infections in neutropenic patients with hematologic malignancies.
Nenova IS; Ananostev NH; Goranov SE; Mateva NG; Haidushka IA
Folia Med (Plovdiv); 2001; 43(4):40-5. PubMed ID: 12087953
[TBL] [Abstract][Full Text] [Related]
35. Clinical impact of fluoroquinolone prophylaxis in neutropenic patients with hematological malignancies.
Chong Y; Yakushiji H; Ito Y; Kamimura T
Int J Infect Dis; 2011 Apr; 15(4):e277-81. PubMed ID: 21324723
[TBL] [Abstract][Full Text] [Related]
36. Infections of febrile neutropenic patients in malignant hematological diseases.
Rókusz L; Liptay L
Mil Med; 2003 May; 168(5):355-9. PubMed ID: 12775168
[TBL] [Abstract][Full Text] [Related]
37. Secondary Infections in Febrile Neutropenia in Hematological Malignancies: More Than Another Febrile Neutropenic Episode.
Demirel A; Tabak F; Ar MC; Mete B; Öngören Ş; Yemişen M; Özaras R; Eşkazan E; Başlar Z; Mert A; Soysal T; Ferhanoğlu B; Aydın Y; Öztürk R
Turk J Haematol; 2015 Sep; 32(3):243-50. PubMed ID: 25913035
[TBL] [Abstract][Full Text] [Related]
38. Impact of fluoroquinolone prophylaxis during neutropenia on bloodstream infection: Data from a surveillance program in 8755 patients receiving high-dose chemotherapy for haematologic malignancies between 2009 and 2014.
Kern WV; Weber S; Dettenkofer M; Kaier K; Bertz H; Behnke M; Weisser M; Götting T; Widmer AF; Theilacker C;
J Infect; 2018 Jul; 77(1):68-74. PubMed ID: 29883599
[TBL] [Abstract][Full Text] [Related]
39. Epidemiology of bloodstream infections in patients with acute myeloid leukemia undergoing levofloxacin prophylaxis.
De Rosa FG; Motta I; Audisio E; Frairia C; Busca A; Di Perri G; Marmont F
BMC Infect Dis; 2013 Dec; 13():563. PubMed ID: 24289496
[TBL] [Abstract][Full Text] [Related]
40. [Antimicrobial prophylaxis and therapy in neutropenia].
Link H
Mycoses; 2003; 46 Suppl 2():21-32. PubMed ID: 15055140
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
